UroNav Fusion Biopsy System

What is a Targeted Prostate Biopsy?

A targeted prostate biopsy is an advanced diagnostic procedure designed to improve the accuracy of prostate cancer detection. One of the most widely used technologies for this approach is the UroNav® Fusion Biopsy system, which combines magnetic resonance imaging (MRI) with real-time ultrasound imaging to create a detailed, three-dimensional view of the prostate. By integrating these imaging methods, physicians can more precisely identify and sample suspicious areas within the prostate that may contain cancer.

Traditional prostate biopsies often rely on randomly sampling tissue from different parts of the prostate. While effective in many cases, this approach may miss smaller or more aggressive tumors. Targeted biopsy technology improves accuracy by allowing physicians to focus directly on areas that appear abnormal on imaging scans.

How a UroNav Fusion Biopsy Works

A UroNav Fusion Biopsy is performed in several steps using advanced imaging and guidance technology.

First, the patient undergoes a multiparametric MRI scan, which produces highly detailed images of the prostate. This imaging allows radiologists to identify suspicious areas that may indicate the presence of cancer.

During the biopsy procedure, the MRI images are digitally fused with real-time ultrasound imaging using the UroNav system. This fusion technology creates a 3D map of the prostate that allows the physician to track the exact location of suspicious areas identified on the MRI.

Using this combined imaging view, the physician carefully guides the biopsy needle directly to the targeted regions. Tissue samples are then collected from these specific areas for laboratory analysis. Because the biopsy is focused on areas most likely to contain cancer, the procedure can improve the likelihood of detecting clinically significant tumors.

Why a UroNav Fusion Biopsy May Be Recommended

A physician may recommend a targeted prostate biopsy for several reasons. One common reason is elevated prostate-specific antigen (PSA) levels, which may indicate an increased risk of prostate cancer.

A UroNav Fusion Biopsy may also be recommended if:

• A patient has persistently elevated PSA levels

• A digital rectal exam (DRE) reveals abnormalities

• A previous biopsy was negative or inconclusive, but suspicion for cancer remains

• A patient with low-risk prostate cancer is undergoing active surveillance and requires careful monitoring for disease progression

In these situations, targeted biopsy technology can provide more detailed information and improve diagnostic confidence.

Benefits of a Targeted Biopsy

Targeted biopsy methods such as the UroNav Fusion Biopsy offer several advantages compared to traditional biopsy techniques:

Improved cancer detection
Suspicious areas identified on MRI can be sampled directly, increasing the chances of detecting clinically significant tumors.

Better identification of aggressive cancers
Targeted biopsies are more likely to identify aggressive tumors that could be missed with random sampling.

More accurate diagnosis
A clearer understanding of the cancer helps physicians recommend the most appropriate treatment plan.

Reduced risk of unnecessary treatment
By improving diagnostic accuracy, targeted biopsies help distinguish between aggressive cancers that require treatment and slower-growing cancers that may only require monitoring.

A More Precise Approach to Prostate Cancer Diagnosis

The UroNav Fusion Biopsy system represents an important advancement in prostate cancer detection. By combining MRI imaging with real-time ultrasound guidance, physicians can perform more precise biopsies and provide patients with clearer diagnostic information. This improved accuracy helps guide treatment decisions and supports earlier detection of clinically significant prostate cancer.

If your physician has recommended a prostate biopsy, discussing the option of a targeted biopsy using UroNav Fusion technology may help ensure the most accurate diagnosis and the best path forward for your care.